Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice
- PMID: 35726313
- PMCID: PMC9206504
- DOI: 10.2147/NDT.S279342
Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice
Abstract
This article provides an updated review of the pharmacological profile and available efficacy and tolerability/safety data for vilazodone, one of the most recent antidepressant drugs to be approved in the USA for the treatment of major depressive disorder (MDD) in adults. The efficacy of vilazodone for MDD in adults is supported by four positive short-term (8-10 weeks), randomized, placebo-controlled trials. Beyond these pivotal trials, we review updated research findings pertaining to the clinical effects of vilazodone for MDD including the results of switch studies, small comparative efficacy trials, key pooled and secondary data analyses focused on important depressive subtypes (anxious depression) and predictors of treatment outcome, and safety studies including direct studies of sexual side-effects. Despite these additional research efforts and use for over a decade, important gaps in the clinical evidence base remain with vilazodone. Hypothesized differences in efficacy and adverse effects between other antidepressants and vilazodone based on its multimodal mechanism of action (combining serotonin reuptake inhibition with serotonin 5-HT1A partial agonist effects) have not been comprehensively demonstrated in clinical studies and its effectiveness as a continuation- or maintenance-phase therapeutic is not yet established. Questions remain regarding its reproductive and lactational safety profiles and its efficacy as a potential next-step therapeutic for patients with MDD who do not respond to first-line antidepressants such as selective serotonin reuptake inhibitors. Suggestions for clinical use of vilazodone and discussion of its place among the broad range of pharmacotherapies for adults with MDD are provided.
Keywords: comparative effectiveness; depression; efficacy; major depressive disorder; safety; vilazodone.
© 2022 Chauhan et al.
Conflict of interest statement
WVB’s research has been supported by NIMH, AHRQ, NSF, the Mayo Foundation for Medical Education and Research, and the Myocarditis Foundation. WVB has contributed chapters to UpToDate regarding the pharmacological treatment of adults with bipolar major depression. The remaining authors report no conflicts of interest.
Figures
Similar articles
-
The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder.Expert Opin Drug Discov. 2016;11(5):515-23. doi: 10.1517/17460441.2016.1160051. Epub 2016 Mar 16. Expert Opin Drug Discov. 2016. PMID: 26971593 Free PMC article. Review.
-
Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Int J Clin Pract. 2012 Apr;66(4):356-68. doi: 10.1111/j.1742-1241.2011.02885.x. Epub 2012 Jan 29. Int J Clin Pract. 2012. PMID: 22284853 Review.
-
The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.Curr Med Res Opin. 2012 Jan;28(1):27-39. doi: 10.1185/03007995.2011.628303. Epub 2011 Nov 23. Curr Med Res Opin. 2012. PMID: 22106941
-
Vilazodone for the treatment of major depressive disorder: focusing on its clinical studies and mechanism of action.Psychiatry Investig. 2015 Apr;12(2):155-63. doi: 10.4306/pi.2015.12.2.155. Epub 2015 Mar 18. Psychiatry Investig. 2015. PMID: 25866514 Free PMC article. Review.
-
An 8-Week Randomized, Double-Blind Trial Comparing Efficacy, Safety, and Tolerability of 3 Vilazodone Dose-Initiation Strategies Following Switch From SSRIs and SNRIs in Major Depressive Disorder.Prim Care Companion CNS Disord. 2015 Aug 6;17(4):10.4088/PCC.14m01734. doi: 10.4088/PCC.14m01734. eCollection 2015. Prim Care Companion CNS Disord. 2015. PMID: 26693034 Free PMC article.
Cited by
-
Receptor Pharmacogenomics: Deciphering Genetic Influence on Drug Response.Int J Mol Sci. 2024 Aug 29;25(17):9371. doi: 10.3390/ijms25179371. Int J Mol Sci. 2024. PMID: 39273318 Free PMC article. Review.
-
Exploring adverse events of Vilazodone: evidence from the FAERS database.BMC Psychiatry. 2024 May 16;24(1):371. doi: 10.1186/s12888-024-05813-0. BMC Psychiatry. 2024. PMID: 38755677 Free PMC article.
-
Treatment-emergent sexual dysfunctions due to antidepressants: A primer on assessment and management strategies.Indian J Psychiatry. 2024 Mar;66(3):293-303. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_784_23. Epub 2024 Mar 18. Indian J Psychiatry. 2024. PMID: 39100123 Free PMC article.
-
SSRIs in the Treatment of Depression: A Pharmacological CUL-DE-SAC?Curr Top Behav Neurosci. 2024;66:1-19. doi: 10.1007/7854_2023_447. Curr Top Behav Neurosci. 2024. PMID: 37922101 Review.
-
Structural pharmacology and therapeutic potential of 5-methoxytryptamines.Nature. 2024 Jun;630(8015):237-246. doi: 10.1038/s41586-024-07403-2. Epub 2024 May 8. Nature. 2024. PMID: 38720072 Free PMC article.
References
-
- World Health Organization. Depression. Fact sheet No. 369; 2012. Available from: www.who.int.medicentre/factsheets/fs369/en/. Accessed October 25, 2015.
-
- Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366. doi:10.1016/S0140-6736(17)32802-7 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources